Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Pancreatic Cancer Cells Vulnerable to Glutamine Pathway Inhibitors

By BiotechDaily International staff writers
Posted on 10 Apr 2013
Print article
Pancreatic cancer cells utilize the amino acid glutamine to fuel their metabolism and are dependent on a single molecular pathway that may be susceptible to pharmaceutical inhibition.

Investigators at the Dana-Farber Cancer Institute (Boston, MA, USA) reported in the March 27, 2013, online edition of the journal Nature that they had identified a noncanonical pathway of glutamine use in human pancreatic ductal adenocarcinoma (PDAC) cells that was required for tumor growth. While most cells use glutamate dehydrogenase (GLUD1) to convert glutamine-derived glutamate into alpha-ketoglutarate in the mitochondria to fuel the tricarboxylic acid cycle (Kreb's cycle), PDAC was shown to rely on a distinct pathway in which glutamine-derived aspartate was transported into the cytoplasm where it was converted into oxaloacetate by aspartate transaminase (GOT1). Subsequently, this oxaloacetate was converted into malate and then pyruvate, increasing the NADPH/NADP+ ratio, which could then maintain the cellular redox state.

PDAC cells were strongly dependent on this series of reactions, as glutamine deprivation or genetic inhibition of any enzyme in this pathway led to an increase in reactive oxygen species and a reduction in reduced glutathione. Moreover, knockdown of any component enzyme in this series of reactions resulted in a pronounced suppression of PDAC growth in vitro and in vivo.

Reprogramming of glutamine metabolism by PDAC was found to be mediated by the KRAS oncogene. The protein product of the normal KRAS (Kirsten rat sarcoma viral oncogene) gene performs an essential function in normal tissue signaling, and its mutation is an essential step in the development of many cancers. A single amino acid substitution is responsible for the activating mutation. The transforming protein that results is implicated in various malignancies, including lung adenocarcinoma, mucinous adenoma, ductal carcinoma of the pancreas, and colorectal carcinoma.

“Pancreatic cancer cells have painted themselves into a metabolic bottleneck,” said senior author Dr. Alec Kimmelman, assistant professor of radiation oncology at the Dana-Farber Cancer Institute. “If you suppress any enzyme in that pathway, the cancer cells cannot effectively compensate and they can no longer grow. We do not have a drug to do this in humans, but we are working on inhibitors of enzymes in the glutamine pathway.”

Related Links:

Dana-Farber Cancer Institute



Print article

Channels

Drug Discovery

view channel
Image: A scanning electron microscope (SEM) image of methicillin-resistant Staphylococcus aureus bacteria (Photo courtesy of the CDC).

Drug Combination Cures MRSA Infection While Preventing Development of Resistance

Treatment with a combination comprising the well-known antibiotic cefdinir and the experimental drug TXA709 cured mice of drug-resistant staphylococcal infections while reducing the development of resistance.... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel
Image: A three-dimensional printer adapted for stem cell production (Photo courtesy of Nano Dimension).

Israeli Developers Demonstrate Prototype Three-Dimensional Bioprinter

Two Israeli companies have combined efforts in the development of three-dimensional printer technology for the production of stem cells. The three-dimensional print electronics developer Nano Dimension... Read more

Business

view channel

Acquisition to Boost Development of Drugs for Neurogenic Conditions

According to a recent announcement, a privately held biotechnology/drug development company is to be acquired by one of the major pharmaceutical manufacturers. The drug manufacturer Merck & Co. (Kenilworth, NJ, USA) has agreed to pay 500 million USD up front for Afferent Pharmaceuticals (San Mateo, CA, USA) and up... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.